

13 October 2016

Resonance Health Commences Involvement in DIASTOLIC study for Diabetes UK

Resonance Health (RHT:ASX) is pleased to announce involvement in the newly commenced DIASTOLIC study on diabetic cardiomyopathy in young adults, led by the highly respected Professor Gerry McCann, Department of Cardiovascular Sciences at the University of Leicester. The NHS funded land-mark DIASTOLIC study which aims to enrol 100 patients over an 18 month timeframe seeks to determine if diet and/or exercise can improve cardiovascular dysfunction in young adults (<40 years) diagnosed with diabetes.

Resonance Health is providing quantitative fat measurements for both the liver and pancreas to monitor how fat changes in response to diet and exercise. A number of patients have now received their baseline MRI scans with measurements being performed on both 1.5T and 3T MRI scanners. This will provide further valuable data for potential validation of Resonance Health's technologies on the 3T platform and expand the market for our technologies.

There has been a rapid rise in obesity related type II diabetes, which affects an estimated 380 million¹ people globally. This has led to an increased prevalence of diabetic cardiomyopathy in younger people, a serious complication that is estimated to reduce life expectancy by around 15 years. The UK National Diabetes Audit 2011 – 12 demonstrated that chronic heart failure is a major cause of premature mortality in patients with type II diabetes. The condition results in a disorder of the heart muscle, which can lead to heart failure and is accompanied by an accumulation of fluid in the lungs or legs.

The prestigious University of Leicester Hospital has used FerriScan in routine clinical practice for a number of years and also established HepaFat-Scan recently for clinical use in addition to use for research in the DIASTOLIC study. Sander Bangma, General Manager, commented:

"The inclusion in this study of a validated technology such as HepaFat-Scan for quantitative measurement of volumetric liver fat fraction (VLFF) together with pancreatic fat assessment aims to provide further data to inform risk thresholds for these patients and monitor response to lifestyle changes or treatment."

¹ Fernandes et al, IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes, Diabetes Research and Clinical Practice 117 (2016)

Tools with the highest sensitivity and specificity are required to measure change and ensure the data has the utmost integrity in a high profile study of this type. We are excited to be exploring use of Resonance Health's technologies in the disease area of diabetes with the team at Leicester who recognise the calibre of our services and the added value we bring as commercial and research partners."

Completion of the DIASTOLIC study is anticipated in early 2018. Initial recruitment is progressing well with over 10 patients already enrolled in the study.

For further information please contact:

Sander Bangma

General Manager, Resonance Health

E: SanderB@resonancehealth.com P: +61 (0)8 9286 5300